-
公开(公告)号：US20240043472A1
公开(公告)日：2024-02-08
申请号：US18377656
申请日：2023-10-06
Applicant: NovMetaPharma Co., Ltd.
Inventor： Kay OLMSTEAD , David Pearson , Elaine Mcpherson
Abstract: The present disclosure relates to synthesis and characterization of novel polymorphic forms of Cyclo (-His-Pro) (“CHP”).
-
公开(公告)号：US20230390279A1
公开(公告)日：2023-12-07
申请号：US18204520
申请日：2023-06-01
Applicant: NOVMETAPHARMA CO., LTD.
Inventor： Keun Gyu Park , In Kyu Lee , Sung Jin Cho , Yeon Kyung Choi , Mi Jin Kim , Jung Wook Chin , Yong Hyun Jeon , Jin A Kim , Dong Su Kim , Hoe Yune Jung , Do Hyun Lee
IPC: A61K31/495 , A61K39/395 , A61P35/00 , A61K31/7105 , A61K31/451 , A61K31/5377 , A61K31/47 , A61K31/506 , A61K31/519
CPC classification number: A61K31/495 , A61K39/3955 , A61P35/00 , A61K31/7105 , A61K31/519 , A61K31/5377 , A61K31/47 , A61K31/506 , A61K31/451
Abstract: A new use of estrogen-related receptor γ (ERRγ) inhibitor in enhancing cancer treatment and a pharmaceutical composition for inhibiting the resistance of cancer to tyrosine kinase inhibitors and enhancing an anticancer effect are disclosed. The pharmaceutical composition contains an ERRγ inhibitor as an active ingredient. The pharmaceutical composition for treating tyrosine kinase inhibitor-resistant advanced cancer. The composition can be administered in combination with tyrosine kinase inhibitor. A method for determining if a cancer is tyrosine kinase-resistant is also disclosed.
-
公开(公告)号：US20230165855A1
公开(公告)日：2023-06-01
申请号：US17912942
申请日：2021-03-19
Applicant: NOVMETAPHARMA CO., LTD. , SEOUL NATIONAL UNIVERSITY HOSPITAL , SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
Inventor： Hoe Yune JUNG , Heon Jong LEE , Yon Su KIM , Seung Hee YANG
IPC: A61K31/4985 , A61P9/12
CPC classification number: A61K31/4985 , A61P9/12
Abstract: New uses of Cyclo-HisPro (CHP) or a salt thereof for lowering blood pressure are disclosed. More specifically, the present invention relates to a pharmaceutical composition for lowering blood pressure, containing CHP or a salt thereof, and a functional health food composition containing CHP or a salt thereof; a method for lowering blood pressure using CHP or a salt thereof; a use of CHP or a salt thereof in the manufacture of antihypertensive agents; a pharmaceutical composition or a functional health food, for preventing or treating hypertension or complications thereof, containing CHP or a salt thereof; a method for preventing or treating hypertension or complications thereof by using CHP or a salt thereof; and a use of CHP or a salt thereof in the manufacture of a medicament for preventing or treating hypertension or complications thereof.
-
公开(公告)号：US11607441B2
公开(公告)日：2023-03-21
申请号：US16757575
申请日：2018-10-19
Applicant: NOVMETAPHARMA CO., LTD.
Inventor： Hoe Yune Jung , Jong Su Jeon , Bo Bae Kim , Heon Jong Lee , Moon Ki Song , Do Hyun Lee
IPC: A61K38/12 , A61P3/10 , A61K31/4439 , A61K31/4985 , A61K31/7034 , A61K33/30
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating diabetes, comprising, as active ingredients: (a) a zinc salt, comprising a zinc cation and anion, and cyclo-hispro, or a pharmaceutically acceptable salt thereof; and (b) an antidiabetic drug (particularly, an insulin sensitizer, an insulin sensitizer, a sodium-glucose co-transporter (a sodium-glucose co-transporter 2 (SGLT2) inhibitor), or a DPP-4 inhibitor).
-
公开(公告)号：US20220331396A1
公开(公告)日：2022-10-20
申请号：US17856729
申请日：2022-07-01
Applicant: NovMetaPharma Co., Ltd.
Inventor： Hoe-Yune JUNG , Heon-Jong LEE , Jong-Su JEON , Yon-Su KIM , Seung-Hee YANG , Yong-Chul KIM , Jong-Joo MOON , Hwan-Soo YOO , Kyeong-Mi CHOI
Abstract: A new use of a cyclo histidine-proline (Cyclo His-Pro, CHP) is disclosed. A composition including cyclo histidine-proline (CHP) as an active ingredient has an excellent protective effect to protect kidney and liver cells from damage and/or toxicity induced by various causes. The composition is useful and effective in protecting kidney and/or liver cells/tissues and in treating a subject with kidney and/or liver diseases and/or damages.
-
Patent Agency Ranking
公开(公告)号：US11433114B2
公开(公告)日：2022-09-06
申请号：US17172879
申请日：2021-02-10
Applicant: NovMetaPharma Co., Ltd.
Inventor： Hoe-Yune Jung , Heon-Jong Lee , Jong-Su Jeon , Yon-Su Kim , Seung-Hee Yang , Yong-Chul Kim , Jong-Joo Moon , Hwan-Soo Yoo , Kyeong-Mi Choi
Abstract: A new use of a cyclo histidine-proline (Cyclo His-Pro, CHP) is disclosed. A composition including cyclo histidine-proline (CHP) as an active ingredient has an excellent protective effect to protect kidney and liver cells from damage and/or toxicity induced by various causes. The composition is useful and effective in protecting kidney and/or liver cells/tissues and in treating a subject with kidney and/or liver diseases and/or damages.
-
公开(公告)号：US20220218793A1
公开(公告)日：2022-07-14
申请号：US17612038
申请日：2020-05-18
Applicant: NOVMETAPHARMA CO., LTD.
Inventor： Hoe Yune JUNG , Do Hyun LEE , Heon Jong LEE
Abstract: A use of a cyclo(his-pro) (CHP) in combination with parathyroid hormone (PTH) and compositions containing the CHP in combination with PTH is disclosed. The combination of CHP and PTH is useful for preventing, improving, or treating a bone loss-related disease. Therefore, a method for treating, preventing, or improving bone loss-related disease in a subject, which includes administering the CHP in combination with PTH is disclosed. The PTH and CHP may be administered to the subject simultaneously, separately, or sequentially.
-
公开(公告)号：US20210401880A1
公开(公告)日：2021-12-30
申请号：US17292238
申请日：2019-11-05
Applicant: Novmetapharma Co., Ltd.
Inventor： Heon Jong Lee , Kay Olmstead , Moon Ki Song , Kyong-Tai Kim , In-Kyu Lee , Hoe-Yune Jung
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating obesity, comprising cyclo-hispro as an active ingredient. Specifically, the present invention has the effect of reducing body weight and body mass, and further improving leptin resistance. In addition, the present invention relates to a pharmaceutical composition for preventing or treating obesity, characterized in that the pharmaceutical composition comprises cyclo-hispro and zinc and is administered once a day.
-
公开(公告)号：US10792280B2
公开(公告)日：2020-10-06
申请号：US16324784
申请日：2017-08-14
Inventor： Kyong Tai Kim , Hoe Yune Jung , Heon Jong Lee
IPC: A61K31/4706 , A61K45/06 , A61K31/155 , A61K31/427 , A61P1/16 , A61P9/00 , A61P3/04 , A61P3/06 , A61P3/10
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating diabetes, and controlling a side effect from peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation, wherein the pharmaceutical composition comprises (a) an amodiaquine compound or a pharmaceutically acceptable salt thereof and (b) an antidiabetic drug as active ingredients. Specifically, the composition prevents or treats simultaneously one or more selected from the group consisting of type 2 diabetes reactive to PPAR-gamma activation, and obesity, dyslipidemia, cardiovascular diseases, and fatty cirrhosis reactive to peroxisome proliferator-activated receptor-alpha (PPAR-alpha) activation.
-
公开(公告)号：US10004727B2
公开(公告)日：2018-06-26
申请号：US15551310
申请日：2016-02-16
Inventor： Kyong Tai Kim , Hoe Yune Jung
IPC: A61K31/4706
CPC classification number: A61K31/4706 , A61K31/47 , A61P1/16 , A61P3/00 , A61P3/04 , A61P3/08 , A61P3/10 , A61P9/00 , A61P9/12
Abstract: The present invention relates to a novel use of a composition containing, as an active ingredient, an amodiaquine compound or a pharmaceutically acceptable salt thereof and specifically, to a metabolic disease prevention, alleviation or treatment use of a composition containing, as an active ingredient, an amodiaquine compound or a pharmaceutically acceptable salt thereof, the composition activating both peroxisome proliferator-activated receptor-gamma (PPAR-γ) and peroxisome proliferator-activated receptor-alpha (PPAR-α).
-
-
-
-
-
-
-
-
-
Search Results
42
records
(took 0.017 seconds)
